Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

(2012) Ligia Traldi Macedo et al.   BMC CANCER

Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer

(2012) Jeffrey A. Meyerhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

(2012) Yuan Su et al.   PLoS One

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

(2011) David Cella et al.   BREAST CANCER RESEARCH AND TREATMENT

Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

(2011) Stephane Ederhy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results?

(2011) Nancy E. Kemeny et al.   ONCOLOGY

Cardiovascular toxicity of anti-angiogenic drugs

(2011) Gaetan des Guetz et al.   Targeted Oncology

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

(2010) Vishal Ranpura et al.   ACTA ONCOLOGICA

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

(2010) Nikol Snoeren et al.   BMC CANCER

Cardiovascular effects of systemic cancer treatment

(2010) Elżbieta Senkus et al.   CANCER TREATMENT REVIEWS

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Complications of Cancer Therapy

(2009) Edward T.H. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

(2009) Markus Moehler et al.   WORLD JOURNAL OF GASTROENTEROLOGY